Premium
Gestrinone in the treatment of menorrhagia
Author(s) -
TURNBULL A. C.,
REES MARGARET C. P.
Publication year - 1990
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1990.tb16244.x
Subject(s) - placebo , medicine , menstruation , hysterectomy , gynecology , blood loss , surgery , pathology , alternative medicine
Summary. The role of gestrinone, 2.5 mg twice weekly, in treating proven menorrhagia (>80 ml) was examined in 19 women. They were treated for five cycles (2 placebo, 3 active), taking one capsule twice weekly. Placebo had no effect on menstrual blood loss (MBL). On gestrinone 10 women became amenorrhoeic, in five MBL was markedly reduced (5–74 ml) and four did not respond. In three of the non‐responders submucous leiomyomas were found at subsequent hysterectomy. Follow‐up periods showed a persistent reduction in MBL for nine women in the first post‐treatment menstruation.